Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal bupivacaine MEC90 for ultrasound-guided suprabrachial plexus block in shoulder arthroscopy
ChiCTR2400084500Phase 4Not yet recruiting
- Sponsor
- Zhuji People's Hospital of Zhejiang Province
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of bupivacaine in Rotator cuff deficiency (RCD), sponsored by Zhuji People's Hospital of Zhejiang Province. Primary endpoint: Minimum effective concentration (MEC90) of liposomal bupivacaine for suprabrachial plexus block. Planned start May 2024; status: not yet recruiting.
02
Drugs
bupivacaine
03
Conditions
Rotator cuff deficiency (RCD)
Beyond the preview
Go deeper on ChiCTR2400084500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084500.